
Incyte frontMIND Trial Shows Tafasitamab Combo Improves PFS in High-Risk DLBCL
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal…












